Corvus Pharmaceuticals (CRVS) Cash from Operations: 2022-2025
Historic Cash from Operations for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to -$9.6 million.
- Corvus Pharmaceuticals' Cash from Operations fell 51.34% to -$9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.1 million, marking a year-over-year decrease of 44.95%. This contributed to the annual value of -$25.4 million for FY2024, which is 6.22% down from last year.
- As of Q3 2025, Corvus Pharmaceuticals' Cash from Operations stood at -$9.6 million, which was down 65.59% from -$5.8 million recorded in Q2 2025.
- In the past 5 years, Corvus Pharmaceuticals' Cash from Operations registered a high of -$5.2 million during Q1 2024, and its lowest value of -$9.6 million during Q3 2025.
- In the last 3 years, Corvus Pharmaceuticals' Cash from Operations had a median value of -$5.8 million in 2025 and averaged -$6.6 million.
- Examining YoY changes over the last 5 years, Corvus Pharmaceuticals' Cash from Operations showed a top increase of 36.42% in 2024 and a maximum decrease of 63.83% in 2024.
- Over the past 4 years, Corvus Pharmaceuticals' Cash from Operations (Quarterly) stood at -$7.5 million in 2022, then skyrocketed by 31.54% to -$5.2 million in 2023, then plummeted by 63.83% to -$8.5 million in 2024, then crashed by 51.34% to -$9.6 million in 2025.
- Its Cash from Operations was -$9.6 million in Q3 2025, compared to -$5.8 million in Q2 2025 and -$8.3 million in Q1 2025.